

September 30, 2025

PROVIDER ALERT:

Dear Prescriber,

The MedStar Family Choice made the decision **to prefer biosimilars for the products listed in table below** in the medical drug formulary **effective November 1, 2025**. This applies to the following place of services (POS); Office- 11, On Campus Outpatient Hospital-22, Public Health Clinic- 71, Home – 12.t

Chemical Name (Drug Class)	HCPCS	Preferred Products	Non-Preferred Products
Aflibercept (VEGF Inhibitor)	Q5147	Pavblu	Eylea (J0178)
Bevacizumab (VEGF Inhibitor)	Q5118	Zirabev	Avastin (J9034) Mvasi (Q5107) Vegzelma (Q5129)
Infliximab (TNF inhibitor)	Q5121	Avsola	Remicade (J1745) Renflexis (Q5104) Inflectra (Q5103)
Pegfilgrastim (Hematopoietic agent)	Q5108	Fulphila	Neulasta (J2506) Fylmetra (Q5130) Nyvepria (Q5122) Stimufend (Q5127) Udenyca (Q5111)
Ranibizumab (VEGF Inhibitor)	Q5128	Cimerli	Lucentis (J2778) Byooviz (Q5124)
Rituximab (Anti-CD20 monoclonal antibody)	Q5123 Q5119	Riabni Ruxience	Rituxan (J9312) Truxima (Q5115)
Tocilizumab (IL-6 antagonist)	Q5135	Tyenne	Actemra (J3262) Tofidence (Q5133)
Trastuzumab (HER2 receptor antagonist)	Q5114 Q5113	Ogivri Herzuma	Herceptin (H9355) Kanjinti (Q5117) Ontruzant (Q5112) Trazimera (Q5116)
Denosumab (RANKL inhibitor)	Q5136 Q5157	Jubbonti/Wyost Stoboclo/Osenvelt	Prolia/Xgeva (J0897)



MedStar Family Choice

DISTRICT OF COLUMBIA

3007 Tilden St., N.W.
Pod 3N
Washington, DC 20008
855-798-4244
MedStarFamilyChoice.com

Ustekinumab (IL-23 inhibitor)	Q5100 Q5099	Yesintek Steqeyma	Stelara (J3357, J3358) Otulfi (Q9999) Selarsdi (Q9998) Wezlana (Q5137) Pyzchiva (Q9996, Q9997)
----------------------------------	----------------	----------------------	--

MedStar Family Choice will continue to cover any existing non-preferred medical drug services that were already approved prior to November 1, 2025.

If you have any questions, please call 202-363-4348.

Sincerely,

Erica McClaskey, MD, MS, FAAFP
Chief Medical Officer DC, Senior Medical Director
MedStar Family Choice DC

**It's how we
treat people.**